| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3282538 | Clinical Gastroenterology and Hepatology | 2014 | 10 Pages |
Abstract
Reinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period.
Keywords
IBDTNFtrough levelIFXROCATIantidrug antibodyantibodies to infliximabLORLoss of responseimmImmunomodulatorInfliximabInflammatory bowel diseaseDrug holidayIntravenousRemicadePharmacokineticsconfidence intervaltumor necrosis factorreceiver operating curvehazard ratioInfusion reactionC-reactive proteinCRP
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, Steve Lockton, Paul Rutgeerts, Séverine Vermeire,